Circulating exosomal PD-L1 at initial diagnosis predicts outcome and survival of patients with osteosarcoma

Jun Wang,Wei Guo,Xiaofang Wang,Xiaodong Tang,Xin Sun,Tingting Ren

DOI: https://doi.org/10.1158/1078-0432.ccr-22-2682

IF: 13.801

2022-11-15

Clinical Cancer Research

Abstract:Purpose: It is difficult to predict prognosis of patients with osteosarcoma (OS) at initial diagnosis due to lack of efficient prognostic parameters. We were currently evaluating the relationship between level of circulating serum exosomal PD-L1 (Sr-exosomal PD-L1) at initial diagnosis and oncologic outcome during the follow-up. Experimental Design: Sixty-seven with newly diagnosed OS were prospectively recruited. Fasting blood was collected and exosome isolation was performed using ultracentrifugation method. Evaluation of Sr-exosomal PD-L1 was performed respectively by immunogold labeling and ELISA method. Correlation between level of Sr-exosomal PD-L1 at initial diagnosis and clinical risk factors was assessed. Results: Mean follow-up was 46.7 months. 2-year and 5-year overall survival rates were respectively 96.9% and 62.5%. 2-year and 5-year disease-free survival rates were respectively 85.0% and 31.4%. Results revealed a significantly positive association between high PD-L1 cargo of circulating exosomes and clinicopathological disease markers such as pulmonary metastasis, multiple metastasis and death. Patients who died of disease at final follow-up had higher level of Sr-exosomal PD-L1 at initial diagnosis, which compared to patients who still alive at last follow-up. Patients in group of ≥14.23 pg/ml Sr-exosomal PD-L1 at initial diagnosis had inferior DFS compared to patients in group of <14.23 pg/ml at initial diagnosis. Patients in group of ≥25.96 pg/ml at initial diagnosis had poor OS compared to patients in group of <25.96 pg/ml at initial diagnosis. Conclusions: Use of liquid biopsy of circulating exosomal PD-L1 at initial diagnosis provides a robust means of predicting prognosis for patients with a newly diagnosed osteosarcoma.

oncology